Patent · US Active

M-CSF specific monoclonal antibody and uses therof

US9522186B2 · kind B2 · utility

1Cited by

13References

22Claims

0Family size

Assignees

Novartis Vaccines and Diagnostics, Inc. · US
XOMA TECHNOLOGY LTD. · US

Inventors

Cheng Liu · Richmond, US
Deborah Lee Zimmerman · Oakland, US
Gregory Martin Harrowe · Eugene, US
Kirston E. Koths · Corona, US
William Michael Kavanaugh · Mill Valley, US
Li Long · Hercules, US
Maria Calderon-Cacia · Castro Valley, US
Arnold Horwitz · San Leandro, US

Key dates

Filing date	Jun 3, 2015
Grant date	Dec 20, 2016
Priority date	—
Expiry date	Jun 3, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.